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Oral Presentations S1830%; MUD, Grade I-II: 20%, Grade III-IV: 20%. CIN of chronic
GVHD was: MSD, limited: 11%, extensive: 0%; MUD, limited:
0%, extensive: 0%. Acute GVHDwas treated to resolution with ste-
roid and ongoing CSA therapy, and all patients weaned from immu-
nosuppression by 1 year. There was no significant difference in
regimen-related morbidity or mortality between MSD and MUD
HCT using this risk-adapted modification of conditioning for
MUD HCT. Though in a limited number of patients, our results
suggest that immunomodulatory TLI/CTX/rATG conditioning is
a promising option for MUD HCT in SAA patients. We propose
to examine this in a prospective clinical trial using CTX/rATG for
MSD HCT versus TLI/CTX/rATG for MUD HCT within 3
months of diagnosis for pediatric and young adult patients with idi-
opathic SAA.79
ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT IN SEVERE
THALASSEMIA PATIENTS IN A SINGLE INSTITUION WITH RELATED
AND UNRELATED DONORS ANDMYELOABLATIVE AND REDUCED INTEN-
SITY REGIMENS
Hongeng, S., Pakakasama, S., Anurathapan, U., Sirachainan, N.,
Songdej, D., Chuansumrit, A. Ramathibodi Hospital, Mahidol University,
Bangkok, Thailand
Recently published reports indicate that the outcome of unrelated
donor hematopoietic stem cell transplantation (HSCT) in patients
with leukemia is comparablewith thatof transplantation from identical
family donors.Wewould like toprove that the outcomesof related and
unrelated transplantation are favorably comparable inchildrenwith se-
vere thalassemia. We reviewed transplant outcome in 87 consecutive
children with severe thalassemia who underwent allogeneic HSCT
the related-donor stem cells (n 5 57) or unrelated-donor stem cells
(n5 30) between September 1992 and July 2010. Analysis of engraft-
ment, frequency of procedure related complications, and thalassemia-
free survival revealed no advantage from use of related-donor stem
cells. The thalassemia-free survival estimate for recipients of related-
donor stem cells was 86% compared with 75% in the unrelated-donor
stemcells group (p50.09).Thepresent studyprovides andevidence to
support the view that it is therefore quite reasonable to consider unre-
lated HSCT as an acceptable therapeutic approach in severe thalasse-
mia, at least for patients who are not fully compliant with conventional
treatment anddonot yet show irreversible severe complications of iron
overload. Moreover, we also have proved that our new reduced inten-
sity conditioning regimen approach can overcome the past poor result
ofHSCT in class 3 lucarelli thalassemia (age$ 10 years) patients (n5
16). Both of the thalassemia free survival and overall survival rates in
this group are 88%.Finally,we have studied the cost utility analysis be-
tweenHSCTandhypertransfusionwith iron chelation therapy in thal-
assemia patients. We can prove that matched related donor
transplantation in thalassemia patients appears to be a cost effective
and affordable treatment for thalassemia patients younger than 10
years of age.80
CLINICAL OUTCOMES OF CHILDREN REQUIRING INTENSIVE CARE FOL-
LOWING HEMATOPOIETIC STEM CELL TRANSPLANTATION
Jodele, S.1, Chima, R.S.2, Butcher, J.2, Wheeler, D.2, Davies, S.M.1
1Cincinnati Children’s Hospital Medical Center, Cincinnati, OH; 2Cin-
cinnati Children’s Hospital Medical Center, Cincinnati, OH
Clinical outcomes for children admitted to the pediatric intensive
care unit (PICU) are improving with advances in supportive care
strategies. We have reviewed outcomes of children admitted to
PICU after hematopoetic stem cell transplantation (HSCT) to de-
termine the likely outcome for this challenging group of patients.
A retrospective review of our PICU and HSCT databases was per-
formed from July 2004 through June 2009. Over this period, 136
HSCT recipients accounted for 260 PICU admissions. Eighty seven
percent of patients (118/136) had allogeneic HSCT and 13% (17/
136) autologous HSCT. Patients admitted to PICU were atincreased risk of subsequent PICU admission, with an average of 2
PICU admissions per patient. Sixty six percent of transplants (90/
136) were myeloablative, 32% (43/136) were reduced intensity and
2% (2/136) were without conditioning regimen (SCID patients).
Eighty six percent of all allogeneic HSCT (102/118) were from un-
related donors. Eighty two percent of admitted patients (213/260)
survived to PICU discharge. Forty three percent of patients are cur-
rently surviving with a median follow up of 2.9 years (1.1-6.1 yrs).
The median PRISM II score for this cohort was 8 (0-47) days, and
median length of stay was 4 days (1-172 days). Thirty nine percent
of admitted (100/260) required intubation and mechanical ventila-
tion and 58% survived to be discharged from the PICU. Forty two
percent of admitted (109/260) required inotropes or vasopressor
support and 66% of these cases survived to PICU discharge. Four-
teen percent of admitted (36/260) required renal replacement ther-
apy and 50% survived to PICU discharge. The LOS, PRISM II
score, and ventilator days were all significantly lower for patients
who survived to PICUdischarge compared to patients who died dur-
ing their PICU admission [LOS (median 3 vs. 13 days, p\ 0.001),
PRISM II score (median 7 vs. 13, p\0.001), ventilator days (median
5 vs. 12 days, p\ 0.002)]. In summary, we report 82% survival to
PICU discharge, with overall 43% survival at a median follow-up
of nearly 3 years for all HSCT patients admitted to our PICU.
Our data suggest improved survival outcomes for this high risk pa-
tient population compared to historical values.81
BLOOD AND NOT URINE BK VIRAL LOAD PREDICTS OUTCOME IN CHIL-
DREN WITH HEMORRHAGIC CYSTITIS AND VIREMIA AFTER STEM CELL
TRANSPLANTATION
Jodele, S.1, Laskin, B.L.2, Bleesing, J.J.1, Mehta, P.A.1, Filipovich, A.H.1,
Marsh, R.A.1, Myers, K.C.1, Jordan, M.B.1, Kumar, A.1,
Grimley,M.S.1, Goebel, J.2, Davies, S.M.1 1Cincinnati Children’s Hospi-
tal Medical Center, Cincinnati, OH; 2Cincinnati Children’s Hospital
Medical Center, Cincinnati, OH
BK virus is a significant cause of hemorrhagic cystitis after stem
cell transplantation (SCT), however, its role in nephropathy post-
SCT is not well studied. We retrospectively evaluated 314 consecu-
tive SCT patients treated at our institution since 2007, when BK
PCR first became clinically available. BK studies were performed
for hematuria or cystitis, not as routine viral screening. Thirty five
SCT patients (11%) had documented hemorrhagic cystitis. Urine
for BK virus was tested in 33/35 patients and was positive in 30
(91%). Average maximum urine viral load was 8 billion copies/
ml, and 73% of patients had a maximum urine viral load . 1 billion
copies/ml. Sixty percent (21/35) of patients with hemorrhagic cystitis
had plasma BK virus tested, and all of them had viremia (n 5 21,
100%). Patients with a maximum plasma viral load of. 10,000 cop-
ies/ml (high viremia; n 5 10) had worse renal outcome and greater
mortality attributed to BK virus compared to patients with #
10,000 copies/ml (low viremia; n 5 11) (table). Specifically, patients
with high viremia had significantly higher creatinine elevation from
pre-SCT baseline. Sixty percent of patients with high plasma viral
load required renal replacement therapy, and half of them developed
end stage renal disease despite BK therapy. Three patients with high
viremia had renal biopsies diagnostic for polyoma virus-associated
nephropathy. Hemorrhagic cystitis was also more severe in the
high viremia group, with half of patients requiring surgical interven-
tions and bladder irrigations for obstructive uropathy. Conversely,
the majority of patients with low viremia had transient elevations
in creatinine and hemorrhagic cystitis that resolved over time. In
summary, BK viremia. 10,000 copies/ml was associated with signif-
icant nephropathy and severe hemorrhagic cystitis following SCT in
our patient cohort. Although majority of SCT patients with hemor-
rhagic cystitis had very high urine viral load, only patients with high
viremia developed nephropathy, end stage renal disease and died
from this infection. Therefore, the degree of viremia, but not viruria,
may identify patients at risk who would benefit from early or aggres-
sive therapy. Future studies should determine optimal monitoring
and treatment protocols for these patients.
S184 Oral PresentationsTable 1. Summary of 21 SCT patients with BK viremia
High Viremia: Low Viremia:
>10,000
copies/ml
(n510)#10,000
copies/ml
(n511)p
valueUrine BK >1 billion copies/ml 8 (80%) 8/10 (80%) p>0.99**
Obstructive uropathy
requiring surgical interventions
5 (50%) 0 (0%) p50.01*Average maximum fold increase in
creatinine from pre-SCT6.4 2.1 p50.02***Renal replacement therapy 6 (60%) 1 (9%)# p50.02*
Biopsy proven polyoma
virus-associated nephropathy
3/3 samples none doneEnd stage renal disease 5 (50%) 0 (0%) p50.01*
Mortality attributed to BK virus 3 (30%) 0 (0%) p50.09*# Not attributed to polyoma virus-associated nephropathy.
*Fisher’s exact test.
**Unconditional exact test.
***Wilcoxon Two-Sample Test.82
HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) IN INFANTS
Leucht, S., Ashraf, K., Schechter, T., Doyle, J., Gassas, A. Hospital for Sick
Children, University of Toronto, Toronto, ON, Canada
Introduction: It is rare for an infant (less than 1 year old) to receive
HSCT and little is known about indications and outcomes in this
high risk population. Our objective herein was to review the indica-
tions and outcomes for all infants who received HSCT in a large
pediatric transplant centre.
Methods: A retrospective analysis of all children who receivedHSCT
was performed. Infants with an underlying immunological disorder
such as severe combined immune deficiency (SCID) were excluded.
Results: Between April 1992 and March 2010, 1363 (allogeneic 775,
autologous 588) children received HSCT in the Hospital for Sick
Children in Toronto. Fifty-one (3.7%) were infants. Seventeen infants
received allogeneic HSCT for an underlying metabolic disorder (os-
teopetrosis 7, Hurler syndrome 7, GM gangliosidosis 1, Niemann-
Pick type A 1 and Krabbes disease 1). The median age of diagnosis
was 78 days (antenatal-248 days). The median age at HSCT was 207
days (29-334 days). They all received myeloablative regimens. For
a median follow-up of 7.1 yrs (0.9-18.4 yrs) 13 patients are alive with
an overall survival in this group of 76%. Causes of death were TRM
in 3 and 1 patient (Niemann-Pick type A) died 4 ½ yrs post HSCT
from progressive disease despite full donor engraftment.
The remaining 34 infants, 10 received autologousHSCT (NBL 3,
AML 2, Brain tumor 3, Rhabdomyosarcoma 1, Retinoblastoma 1).
Twenty-four infants received allogeneic HSCT (13 related, 11 unre-
lated)- HLH 8, JMML 4, WAS 4, ALL 3, AML 2, SAA 1, CGD 1
and Amegakaryocytic Thrombocytopenia 1.Median age at diagnosis
was 103 days (1-200 days), median age at HSCT was 254 days (142-
365 days). All patients receivedmyeloablative regimens. For amedian
follow-up of 6.7 yrs (0.5-15.6 yrs) 25 infants are alive with an overall
survival in this group of 73%. Nine infants (27%) died, 6 due to
TRM and 3 because of disease relapse.
Eight out of ten infants who received autologous HSCT are long
term survivors.
Early post HSCT complications for all patients were mainly related
to feeding issues requiring long termNG/GT feeding. In terms of de-
velopmental and long term outcomes, the majority were delayed in
their developmental milestones at 12 months of age. However, most
of them caught up later on and attained good performance scales.
Conclusion: Our results for HSCT in infants are very encouraging
with good long term developmental mile stones and excellent
functional long term survival.83
STEM CELL TRANSPLANTATION FOR CD3-DELTA DEFICIENCY
Marcus, N.1, Takada, H.2, Dalal, J.3, Regueiro, J.R.4, Friedrich, W.5,
Roifman, C.1 1University of Toronto & Affiliated Hospitals, Toronto,ON, Canada; 2Kyushu University, Fukuoka, Japan; 3University of Mis-
souri-Kansas City School of Medicine, Kansas City, MO; 4Universidad
Complutense, Madrid, Spain; 5Universit€atskinderklinik, Ulm, Germany
Rational:CD3-delta deficiency is a rare fatal form of SCID which is
potentially cured by hematopoetic stem cell transplantation
(HSCT). Being a rare disease optimal transplantation protocols for
this group of patients has not been established.
Methods: We retrospectively analyzed the data on 9 patients with
CD3-delta deficiency from 5 centers in Japan North America and
Europe that underwent HSCT, using different sources of donor
stem cells and different conditioning regimens.
Results:Mean age at HSCT was 5 months. 3 patients received stem
cells from a matched unrelated donor (MUD), with myeloablative
conditioning. They are alive and well. All of them experienced rapid
engraftment and full immune reconstitution. One of these patients
has recently delivered a healthy baby girl, 18y post BMT. 2 patients
received a matched cord transplant without conditioning. One of
them has had a partial but stable engraftment, while the other en-
grafted well but has only been followed for 12 months after
HSCT. Two other patients received a mismatched related donor
(MMRD). Both theses patients had failed to engraft and finally
died. Another 2 patients received stem cells from a matched related
donor (MRD), one with reduced conditioning regimen. This patient
lost his graft and recently underwent a second BMT. The other pa-
tient who received full conditioning is doing well and achieved full
immune reconstitution as well.
Conclusions: HSCT from MUD was successful. Myeloablative
conditioning may be necessary for engraftment of bone marrow de-
rived stem cells in these patients. It’s interesting to speculate that
cord stem cells may override that need.84
EXCELLENT SURVIVAL AFTER STEM CELL TRANSPLANTATION FOR NON-
SCID PRIMARY IMMUNODEFICIENCIES
Martinez, C.A.1, Hanson, I.C.2, Rosenblatt, H.M.3, Chinen, J.2,
Leung, K.1, Kennedy-Nasser, A.1, Craddock, J.1, Brenner, M.1,
Heslop, H.1, Chokshi, N.4, Shearer, W.2, Krance, R.1 1Texas Children’s
Cancer Center, Baylor College of Medicine, Houston, TX; 2Texas Child-
ren’s Hospital, Baylor College of Medicine, Houston, TX; 3Dell Children’s
Medical Center of Central Texas, Austin, TX; 4Texas Children’s Hospital,
Baylor College of Medicine, Houston, TX
Allogeneic hematopoietic stem cell transplantation (HSCT) for
patients with Primary Immunodeficiencies (PIDs) has provided
a life saving therapy. There is less information available regarding
the utilization of stem cell transplantation for children with PIDs
other than SCID. We report the outcome following HSCT (1998-
2010) in 31 non-SCID patients: WAS (n 5 6), CGD (n 5 12),
LAD (n 5 3); and other T cell defects (n 5 10). The T cell defects
group included patients with NK cell defects (n5 2), X-linked lym-
phoproliferative disease (n5 2), NEMO (n5 1), HLA-class II defi-
ciency (n 5 1), Hyper IgM syndrome (n 5 1), DiGeorge Anomaly
(n 5 2) and Zap 70 deficiency (n 5 1). The patient median age at
transplant was 2.5 years (range, 0.3-16 years). Fourteen patients
received a matched related donor graft (MRD), thirteen patients re-
ceived a matched unrelated donor graft (MUD), two patients re-
ceived a mismatched unrelated donor graft and two patients
received a mismatched unrelated cord blood unit. Most patients (n
5 25) received a myeloblative conditioning consisting of busulfan,
cyclophosphamide, and fludarabine or cytarabine. Two patients re-
ceived total body radiation at 1400Gy. Only four patients received
a sub-myeloablative conditioning with cyclophosphamide and bu-
sulfan backbone with or without fludarabine. Two patients with
complete DiGeorge Syndrome were not conditioned. Graft vs host
disease (GvHD) prophylaxis usually combined cyclosporine and
metrotrexate or cyclosporine and prednisone.Most patients received
Campath to improve engraftment and to prevent GvHD. The me-
dian time for neutrophil recovery was 18 days (range, 12-37 days).
Twenty four patients achieved full donor chimerism (donor chime-
rism . 95%) and seven patients achieved mixed donor chimerism
(mean: 70%, range, 40-90%) but with correction of defective im-
mune function. There was no incidence of graft failure. Eight pa-
tients developed grade I aGvHD requiring only topical treatment.
Only one patient developed grade II-IV aGvHD. Chronic GvHD
